Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that it began shipping its generic version of Attention Deficit Hyperactivity Disorder (ADHD) treatment Adderall.
Teva developed a generic version of Shire Pharmaceuticals’ Adderall XR (mixed salts of a single-entity amphetamine product) capsules, 5mg, 10mg, 15mg, 20mg, 25mg and 30 mg. The drug is used to treat Attention Deficit Hyperactivity Disorder (ADHD).
Based on IMS sales data, annual sales of Adderall XR were approximately $1.5 billion in the United States for the twelve months that ended February 28, 2009.
In August 2006, Teva’s subsidiary Barr Pharmaceuticals, Inc. entered into a license agreement with Shire as part of a settlement of patent litigation between the parties. Under this agreement, Shire granted the company the exclusive right to sell a generic version of Adderall XR Capsules for 180 days from the date of commercial launch.
Shares in Teva closed down 2.2% today at $44.44, giving it a market cap of $39.49 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on April 3, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009